Brief: Ac Immune’S Alzheimer’S Disease Vaccine-Candidate Selected For Further Development
30/11/2022 12:20
Nov 30 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE’S ALZHEIMER’S DISEASE VACCINE-CANDIDATE
ACI-35.030
SELECTED FOR FURTHER DEVELOPMENT
* AC IMMUNE SA - DATA PRESENTED AT CTAD 2022 CONFIRM
EXCELLENT
CLINICAL PERFORMANCE OF ACI-35.030 VACCINE CANDIDATE
Source text for Eikon: ID:nGNX8bbLKy
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture